Aha: Mixed Results With Dapagliflozin In T2d Patients | Latest News RSS feed

Aha: Mixed Results With Dapagliflozin In T2d Patients - Latest News

AHA: Mixed Results with Dapagliflozin in T2D Patients

CHICAGO -- Dapagliflozin (Farxiga) did not led to a difference in the rate of major adverse cardiovascular events (MACE) in diabetic patients with or at risk for atherosclerotic cardiovascular disease ... read more

Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure

Results from the 17,000-patient ... for dapagliflozin, the sodium glucose co-transporter 2 (SGLT2) inhibitor sold as Farxiga (AstraZeneca), presented today at the American Heart Association (AHA) annu... read more

Forxiga significantly reduced hospitalisation for...

MISSISSAUGA, ON, Nov. 10, 2018 /CNW/ - AstraZeneca today announced positive full results from ... for Forxiga (dapagliflozin). The data were presented as a late-breaking abstract (#19485) at the Ameri... read more

Looking for another news?

The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018

Presentations will include findings from some of the largest trials in broad patient populations with FARXIGA (dapagliflozin) in type 2 diabetes (T2D), BRILINTA (ticagrelor ... Clinical trial results ... read more

Bristol-Myers Squibb CEO Discusses Q3 2013 Results - Earnings Call Transcript

Yervoy results in the U.S. were also positive, notwithstanding the impact of a significant number of new clinical trials targeting melanoma patients with other agents ... showed encouraging gains. And ... read more

What are the determinants associated with fasting hyperglucagonemia in type 2 diabetes?

A new study examined the relationship between fasting hyperglucagonemia—which can negatively affect glucose metabolism in patients ... (T2D)—and several biochemical and glycemic factors in subjects wi... read more

SGLT-2 Inhibitors: A New Mechanism for Glycemic Control

Dapagliflozin has been shown to be effective in patients with early type 2 diabetes (i.e., treatment-naive patients), as well as in patients dependent on insulin plus insulin sensitizers. 62 A pooled ... read more

Professor Dendy and the most common creationist canard

That sad creationist, Professor Dendy, has been banned from this site, but he still rails against us in prolific obsession from his website. His latest diatribe is irresistible — he claims that atheis... read more

AstraZeneca's CEO Discusses Q4 2012 Results - Earnings Call Transcript

Welcome to our 2012 full-year results presentation ... In the fourth quarter, Brilinta was added to the ACCF/AHA guidelines for the management of patients with ST-elevation myocardial infarction eleva... read more

The landmark DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga in patients with type-2 diabetes to be featured at AHA 2018

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase ... of the largest trials in broad patient populations with Farxiga (dapagliflozin) ... read more

Researchers discovered a new mechanism of action in a first-line drug for diabetes

while podocyte loss was also lower than in patients using another drug therapy. "Our results indicate that the lipid phosphatase SHIP2 has a significant role in regulating glucose metabolism and cell ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us